A clear connection between IL-1β and Cardiovascular Disease

A recent publication in the NEJM describes a high profile clinical trial (CANTOS) in which heart attack patients treated with canakinumab, a selective antibody that inhibits IL-1β, demonstrated a 15% reduction in heart disease and stroke.1  The trial also recorded fewer cases of lung cancer, consistent with the hypothesis that the same inflammatory pathway contributes to lung cancer.2

How do you measure IL-1β in blood samples?

Circulating levels of IL-1β are very low and rarely detectible with acceptable precision using standard immunoassays. Now, with Myriad RBM’s Ultrasensitive Simoa IL-1β immunoassay,  >90% of samples have IL-1β levels above LLOQ.

RBM’s Ultrasensitive Simoa IL-1β Immunoassay
Plasma/Serum LLOQ = 0.031 pg/ml

In light of these new findings, important questions on the prognostic and predictive potential of IL-1β in CVD can now be explored with this ultrasensitive assay.

Let us help advance your cardiovascular research with our ultrasensitive IL-1β Simoa immunoassay!

  1. Ridker PM, et. al.  (2017). Anti-inflammatory Therapy with Canakinumab for Atherosclerotic Disease. NEJM DOI: 10.1056/NEJM 1707914
  2. Ridker PM, et. al. (2017). Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients withatherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.  Lancet  DOI: 10.1016/S0140-6736(17)32247-X.